GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Nova Mentis Life Science Corp (OTCPK:NMLSF) » Definitions » Gross Profit

Nova Mentis Life Science (Nova Mentis Life Science) Gross Profit : $0.02 Mil (TTM As of Mar. 2024)


View and export this data going back to 2013. Start your Free Trial

What is Nova Mentis Life Science Gross Profit?

Nova Mentis Life Science's gross profit for the three months ended in Mar. 2024 was $0.00 Mil. Nova Mentis Life Science's gross profit for the trailing twelve months (TTM) ended in Mar. 2024 was $0.02 Mil.

Gross Margin % is calculated as gross profit divided by its revenue. Nova Mentis Life Science's gross profit for the three months ended in Mar. 2024 was $0.00 Mil. Nova Mentis Life Science's Revenue for the three months ended in Mar. 2024 was $0.00 Mil. Therefore, Nova Mentis Life Science's Gross Margin % for the quarter that ended in Mar. 2024 was N/A%.

Nova Mentis Life Science had a gross margin of N/A% for the quarter that ended in Mar. 2024 => No sustainable competitive advantage

During the past 13 years, the highest Gross Margin % of Nova Mentis Life Science was 28.57%. The lowest was 18.18%. And the median was 23.38%.


Nova Mentis Life Science Gross Profit Historical Data

The historical data trend for Nova Mentis Life Science's Gross Profit can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Nova Mentis Life Science Gross Profit Chart

Nova Mentis Life Science Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Gross Profit
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Nova Mentis Life Science Quarterly Data
Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Sep23 Mar24
Gross Profit Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - 0.02 -

Competitive Comparison of Nova Mentis Life Science's Gross Profit

For the Biotechnology subindustry, Nova Mentis Life Science's Gross Profit, along with its competitors' market caps and Gross Profit data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Nova Mentis Life Science's Gross Profit Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Nova Mentis Life Science's Gross Profit distribution charts can be found below:

* The bar in red indicates where Nova Mentis Life Science's Gross Profit falls into.



Nova Mentis Life Science Gross Profit Calculation

Gross Profit is the different between the sale prices and the cost of buying or producing the goods.

Nova Mentis Life Science's Gross Profit for the fiscal year that ended in Dec. 2022 is calculated as

Gross Profit (A: Dec. 2022 )=Revenue - Cost of Goods Sold
=0 - 0
=0.00

Nova Mentis Life Science's Gross Profit for the quarter that ended in Mar. 2024 is calculated as

Gross Profit (Q: Mar. 2024 )=Revenue - Cost of Goods Sold
=0 - 0
=0.00

Gross Profit for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.02 Mil.

Gross Profit is the numerator in the calculation of Gross Margin. (Note that if there's no value for Cost of Goods Sold, then Gross Margin % is not calculated.)

Nova Mentis Life Science's Gross Margin % for the quarter that ended in Mar. 2024 is calculated as

Gross Margin % (Q: Mar. 2024 )=Gross Profit (Q: Mar. 2024 ) / Revenue (Q: Mar. 2024 )
=(Revenue - Cost of Goods Sold) / Revenue
=0.00 / 0
=N/A %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.


Nova Mentis Life Science  (OTCPK:NMLSF) Gross Profit Explanation

Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.

Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %

1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key

Nova Mentis Life Science had a gross margin of N/A% for the quarter that ended in Mar. 2024 => No sustainable competitive advantage


Nova Mentis Life Science Gross Profit Related Terms

Thank you for viewing the detailed overview of Nova Mentis Life Science's Gross Profit provided by GuruFocus.com. Please click on the following links to see related term pages.


Nova Mentis Life Science (Nova Mentis Life Science) Business Description

Traded in Other Exchanges
Address
700-838 West Hastings Street, Vancouver, BC, CAN, V6C 0A6
Nova Mentis Life Science Corp is a Canadian-based biotechnology company. It is engaged in developing diagnostics and psilocybin-based therapeutics for neuroinflammatory disorders. Nova uses psilocybin in the treatment of Fragile X Syndrome (FXS). The company's goal is to diagnose and treat debilitating chronic conditions that have unmet medical needs such as autism spectrum disorder (ASD) and FXS. It has one industry segment, being research and development of psilocybin, and in one geographic area, which is Canada.

Nova Mentis Life Science (Nova Mentis Life Science) Headlines

From GuruFocus

Nova Mentis Announces Closing of Non-Brokered Financing

By PRNewswire PRNewswire 03-15-2022